The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Open accessAbstract
Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that psilocybin may decrease depression and anxiety in cancer patients. The effects of psilocybin were studied in 51 cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety. This randomized, double-blind, cross-over trial investigated the effects of a very low (placebo-like) dose (1 or 3 mg/70 kg) vs. a high dose (22 or 30 mg/70 kg) of psilocybin administered in counterbalanced sequence with 5 weeks between sessions and a 6-month follow-up. Instructions to participants and staff minimized expectancy effects. Participants, staff, and community observers rated participant moods, attitudes, and behaviors throughout the study. High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety. At 6-month follow-up, these changes were sustained, with about 80% of participants continuing to show clinically significant decreases in depressed mood and anxiety. Participants attributed improvements in attitudes about life/self, mood, relationships, and spirituality to the high-dose experience, with >80% endorsing moderately or greater increased well-being/life satisfaction. Community observer ratings showed corresponding changes. Mystical-type psilocybin experience on session day mediated the effect of psilocybin dose on therapeutic outcomes. Trial Registration ClinicalTrials.gov identifier: NCT00465595
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In this study, groups of healthy participants were randomized into three groups, (1) low-dose psilocybin with standard support for spiritual practice (SS); (2) high-dose psilocybin with SS, and (3) high-dose psilocybin with High Support (HS) for spiritual practice.”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [6]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Griffiths et al. (2016)(n = 51) reported significantly larger response (92% versus 32%) and remission (60% versus 1%) on depression and anxiety (76% vs. 24%; 52% vs. 12%, respectively) in the high-dose group compared to active placebo after 5 weeks.”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Griffiths et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Griffiths et al. (2016)(n = 51) reported significantly larger response (92% versus 32%) and remission (60% versus 1%) on depression and anxiety (76% vs. 24%; 52% vs. 12%, respectively) in the high-dose group compared to active placebo after 5 weeks.”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Griffiths et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most of this research has been carried out with the Revised Mystical Experience Questionnaire 30 (MEQ30), where a high score correlates with and has been suggested as a predictor of long-term positive therapeutic outcomes in various clinical and naturalistic studies of psychedelics.”
From Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics (2024) · cites this paper as Griffiths et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Not only do they produce sustained therapeutic effects following a single administration, they also appear to have broad therapeutic potential”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [40]
Experimental — accuracy not yet measured
52 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
(2013) · Cited by 44,563
(1970) · Cited by 24,983
Depression and quality of life in older persons: A review
Sivertsen, H., Bjørkløf, G. H., Engedal, K., Selbæk, G., & Helvik, A.-S. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000437299 · Cited by 14,152
Optimism, coping, and health: Assessment and implications of generalized outcome expectancies.
Scheier, M. F., & Carver, C. S. (1985) · Health Psychology · doi:10.1037/0278-6133.4.3.219 · Cited by 6,690 · cited 2×
“…existence (existential subscale) during life-threatening illness (Cohen et al., 1995); LOT-R, self-rated optimism measure associated with illness (Scheier and Carver, 1985); LAP-R Death Acceptance, selfrated scale assessing absence of anxiety about death (Reker, 1992); Death Transcendence Scale,…”
BackgroundMethodMcNair, D. M. (1992) · Medical Entomology and Zoology · Cited by 2,531
Mitchell, A. J., Chan, M., Bhatti, H., Halton, M., Grassi, L., Johansen, C., & Meader, N. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70002-x · Cited by 2,449 · cited 1×
“Cancer patients often develop a chronic, clinically significant syndrome of psychosocial distress having depressed mood, anxiety, and reduced quality of life as core features, with up to 40% of cancer patients meeting criteria for a mood disorder (Holland et al., 2013; Mitchell et al., 2011).”
BackgroundNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762 · cited 2×
“The classic hallucinogens, which include psilocybin (psilocin) and (+)-lysergic acid diethylamide (LSD), are a structurally diverse group of compounds that are 5-HT2A receptor agonists and produce a unique profile of changes in thoughts, perceptions, and emotions (Halberstadt, 2015; Nichols, 2016).”
BackgroundPeterman, A. H., Fitchett, G., Brady, M. J., Hernandez, L., & Cella, D. (2002) · Annals of Behavioral Medicine · doi:10.1207/s15324796abm2401_06 · Cited by 1,751 · cited 2×
“Three measures of spirituality were assessed at three time-points: Baseline, 5 weeks after session 2, and at the 6-month follow-up: FACIT-Sp, a self-rated measure of the spiritual dimension of quality of life in chronic illness (Peterman et al., 2002) assessed on how the participant felt “on average”; Spiritual-Religi…”
MethodGriffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 18×
“The structured interview (Community Observer Questionnaire) consisted of asking the rater to rate the participant’s behavior and attitudes using a 10-point scale (from 1 = not at all, to 10 = extremely) on 13 items reflecting healthy psychosocial functioning: inner peace; patience; good-natured humor/playfulness; ment…”
BackgroundMethodResultInfluentialSelf-citation
Research works printed but not linked: 9
- Beck AT, 1987, BDI Beck Depression Inventory Manual
- Benson PL, 1993, Res Soc Sci Stud Religion, 5, 1
- Carhart-Harris RL, 2014, Front Human Neurosci, 8, 1
- ISCDD, 2003, GRID-HAMD-17 Structured Interview Guide
- McIntosh DN, 1999, Measures of Religiosity, 503
- Metzner R, 1965, Psychedelic Rev, 5, 3
- Ostuzzi G, 2015, Cochrane Database Syst Rev, 6, CD011006
- Reker GT, 1992, The Life Attitude Profile-Revised (LAP-R)
- VandeCreek L, 1999, Measures of Religiosity, 442
Cited by
Trial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Self-citationREBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206443 · Cited by 1,167
“Any severe adverse event 7 (9) 5 (7) 1 (1)”
BackgroundPsilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
“Recent studies (Griffiths et al. 2016; Ross et al. 2016; Carhart-Harris et al. 2016), including the present one, help demonstrate the feasibility of treating patients with major depressive disorder with psilocybin plus psychological support.”
BackgroundResultInfluential
Metadata
- Authors
- Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Griffiths, Roland R
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2016-11-30
- Volume
- 30
- Issue
- 12
- Pages
- 1181-1197
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC5367557
- OpenAlex
- W2558412547
- Cited by
- 2,201
- References
- 53
- Citations by year
- 2026: 278 · 2025: 325 · 2024: 335 · 2023: 315 · 2022: 310 · 2021: 229 · 2020: 187 · 2019: 73 · 2018: 77 · 2017: 54 · 2016: 14
- FWCI
- 97.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Drug Abuse (R01DA003889)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Keywords
- psilocybin, depression, anxiety, cancer patients, psychedelic therapy, dose-response relationship, mystical experience, fear of death, quality of life, meaning of life, optimism, well-being, sustained treatment effects
- MeSH terms
- Anxiety, Attitude, Depression, Double-Blind Method, Female, Follow-Up Studies, Hallucinogens, Humans, Male, Middle Aged, Neoplasms, Psilocybin, Quality of Life, Surveys and Questionnaires, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. https://app.cochat.ai/papers/10.1177/0269881116675513
- The paper
- Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology. https://doi.org/10.1177/0269881116675513
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.